Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K

Prostate

Volumn 63, Issue 1, 2005, Pages 44-55

  Gutiérrez Cañas, Irene ^a   Juarranz, María G ^a,b   Collado, Beatriz ^a   Rodríguez Henche, Nieves ^a   Chiloeches, Antonio ^a   Prieto, Juan C ^a   Carmena, María J ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

LNCaP; NE differentiation; Prostate cancer; Protein kinases; VIP

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; GUANOSINE TRIPHOSPHATE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NEURON SPECIFIC ENOLASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; RECEPTOR SUBTYPE; VASOACTIVE INTESTINAL POLYPEPTIDE; WORTMANNIN;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; NEUROSECRETORY CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA, NEUROENDOCRINE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUROPROTECTIVE AGENTS; PROSTATIC NEOPLASMS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 14944356887     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20173     Document Type: Article

References (41)

1. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003;17:1726-1737.
2. Gkonos PJ, Krongrad A, Roos BA. Neuroendocrine peptides in the prostate. Urol Res 1995;23:81-87.
3. Aprikian AG, Han K, Guy L, Landry F, Begin LR, Chevalier S. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate 1998;36(S8):52-61.
4. Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995;26:167-170.
5. Reubi JC, Läderach V, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000;60:3105-3112.
6. Moody TW, Chan D, Fahrenkrug J, Jensen RT. Neuropeptides as autocrine growth factors in cancer cells. Curr Pharmaceut Design 2003;9:495-509.
7. Juarranz MG, Bodega G, Prieto JC, Guijarro LG. Vasoactive intestinal peptide (VIP) stimulates rat prostatic epithelial cell proliferation. Prostate 2001;42:285-292.
8. Juarranz MG, Bolaños O, Gutierrez-Cañas I, Lerner EA, Robberecht P, Carmena MJ, Prieto JC, Rodriguez-Henche N. Neuroendocrine differentiation of LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell Signal 2001;13:887-894.
9. Farini D, Puglianiello A, Mammi C, Siracusa G, Moretti C. Dual effect of pituitary adenylate cyclase activating polypeptide on prostate tumor LNCaP cells: Short- and long-term exposure affect proliferation and neuroendocrine differentiation. Endocrinology 2003;144:1631-1643.
10. Gutierrez-Cañas I, Rodriguez-Henche N, Bolaños O, Carmena MJ, Prieto JC, Juarranz MG. VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. Br J Pharmacol 2003;139:1050-1058.
11. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. Pharmacol Rev 1998;50:265-270.
12. 1 subtype is predominant in rat prostate membranes. Prostate 1999;41:1-6.
13. Carmena MJ, Sancho JI, Prieto JC. Effects of age and androgens upon functional vasoactive intestinal peptide receptors in rat prostatic epithelial cells. Biochim Biophys Acta 1986;888:338-343.
14. Juarranz MG, Guijarro LG, Bajo AM, Carmena MJ, Prieto JC. Ontogeny of vasoactive intestinal receptors in rat ventral prostate. Gen Pharmacol 1994;25:509-514.
15. Carmena MJ, Prieto JC. Cyclic AMP-stimulating effect of vasoactive intestinal peptide in isolated epithelial cells of rat ventral prostate. Biochim Biophys Acta 1983;463:414-418.
16. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Nikilinski WT, Myers CE, Trepel JB. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994;91: 5330-5334.
17. Cox ME, Deeble PD, Bissonette EA, Parsons SJ. Activated 3′,5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 2000;275:13812-13818.
18. Wong HC, Sternini C, Lloyd K, De Giorgio R, Walsh JH. Monoclonal antibody to VIP: Production, characterization, immunoneutralizing activity, and usefulness in cytochemical staining. Hybridoma 1996;15:133-139.
19. Bradford MA. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of the protein-dye binding. Anal Biochem 1976;78:248-254.
20. Chang JT, Chen IH, Liao CT, Wang HM, Hsu YM, Hung KF, Lin CJ, Hsieh LL, Cheng AJ. A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem 2002;35:591-596.
21. De Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 1997; 14:623-625.
22. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998;58: 2720-2723.
23. Chung LW. The role of stromal-epithelial interactions in normal and malignant growth. Cancer Surv 1995;23:33-42.
24. Tainio H. Peptidegic innervation of the human prostate, seminal vesicle, and vas deferens. Acta Histochem 1995;97: 113-119.
25. García-Fernández O, Bodega G, Solano RM, Ruíz-Villaespesa A, Sánchez-Chapado M, Carmena MJ, Prieto JC. Expression and distribution of pituitary adenylate cyclase-activating polypeptide in human prostate and prostate cancer tissue. Regul Peptides 2002;110:9-15.
26. Chen T, Cho RW, Stork PJS, Weber MJ. Elevation of cyclic adenosine 3′, 5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 1999;59:213-218.
27. Gutkind JS. Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Sci STKE 2000;40:1-13.
28. Kim J, Adam RM, Freeman MR. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT phosphorylation. Cancer Res 2002;62: 1549-1554.
29. Thomson S, Clayton AL, Hazzalin CA, Rose S, Barratt MJ, Mahadevan LC. The nucleosomal response associated with immediate-early genes induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J 1999;18:4779-4793.
30. Vossler MR, Yao H, York RD, Pan MG, Rim CS, Stork PJS. cAMP activates MAP kinase and Elk-1 through a B-Raf and Rap1-dependent pathway. Cell 1997;89:73-82.
31. Bouschet T, Perez V, Fernández C, Bockaert J, Eychene A, Journot L. Stimulation of the ERK pathway by GTP-loaded Rap1 requires the concomitant activation of Ras, protein kinase C, and protein kinase A in neuronal cells. J Biol Chem 2003;278: 4778-4785.
32. Alleaume C, Eychène A, Caigneaux E, Muller JM, Philippe M. Vasoactive intestinal peptide stimulates proliferation in HT29 human colonic adenocarcinoma cells: Concomitant activation of Ras/Rap1-Braf-ERK signaling pathway. Neuropeptides 2003; 37:98-104.
33. De Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998; 396:474-477.
34. Goi T, Rusanesku G, Urano T, Feig LA. Ral-specific guanine nucleotide exchange factor activity opposes other Ras effectors in PC12 cells by inhibiting neurite outgrowth. Mol Cell Biol 1999;19:1731-1741.
35. Kronengurg O, Moolenaar WH. Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene 2001;20:1540-1546.
36. Yart A, Roche S, Wetzker R, Laffargue M, Tonks N, Mayeux P, Chap H, Raynal P. A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J Biol Chem 2002;277:21167-21178.
37. Craddock BL, Hobbs J, Edmead CE, Welham MJ. Phosphoinositide 3-kinase-dependent regulation of interleukin-3-induced proliferation: Involvement of mitogen-activated protein kinases, SHP2 and Gab2. J Biol Chem 2001;276:24274-24283.
38. Lahlou H, Saint-Laurent N, Esteve JP, Eychene A, Pradayrol L, Pyronnet S, Susini C. Sst2 somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003;278:39356-39371.
39. King AJ, Sun H, Diaz B, Barnard D, Miao W, Bagrodia S, Marshall MS. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 1998;396: 180-183.
40. Chaudhary A, King WG, Mattaliano MD, Frost JA, Diaz B, Morrison DK, Cobb MH, Marshall MS, Brugge JS. Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr Biol 2000;10:551-554.
41. Chiloeches A, Mason CS, Marais R. S338 phosphorylation of Raf1 is independent of phosphatidylinositol 3-kinase and Pak3. Mol Cell Biol 2001;21:2423-2434.